Sign In
Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
CNTA.US
id: 329, Created by Stan Vick, Scout

Centessa Pharmaceuticals PLC ADR

C.D. California
Court
On June 1, 2021, Centessa filed a prospectus with the SEC in connection with the IPO. The Company issued 16.5 million of its ADSs to the public at the Offering price of $20 per ADS, for proceeds of $306.9 million.

Further, after the IPO, in 2021 and 2022, in the course of press releases and reports, the Company released news that had a negative impact on the share price. In particular:
  • On November 1, 2021, Centessa issued a press release announcing results from the Phase 1 study evaluating ZF874 in treating AATD, including, among other results, potential safety issues related to increases in liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in one of the study subjects.
  • On June 2, 2022, the Company announced that "it has made the strategic decision to discontinue development of lixivaptan for (ADPKD)” citing “a recent observation of ALT and AST elevations in one subject” from a Phase 3 study of lixivaptan that was designed to assess liver and non-liver safety in certain subjects.
  • On August 10, 2022, Centessa announced its decision "to discontinue development of ZF874 following a recent report of an adverse event involving elevated liver enzymes (AST/ALT) in a . . . subject dosed with 5 mg/kg BID of ZF874 in the Phase 1 study.”  The Company concluded that “based on the results observed to date, the Company concluded that ZF874 was unlikely to achieve the desired target product profile.”
Taking the information and representations that were disclosed to investors during the IPO and subsequent results into account, investors have reasons to suspect that the Company, its Leaders, and other entities involved in the organization of the IPO did not properly disclose the information and the statements made did not correspond to reality.

Alleged Offence
Misleading Statements
Failure to Disclose
Negligence
Breach of Fiduciary duty
Omissions
Suspected Party
Directors
Management
Investment Bank
Service Provider
Security Type
Depository Securities (ADS, ADR, GDR)
Trade Direction
Long
Shock Event Date
01 June 2021
Collecting participants…
Created by Stan Vick, Scout

Centessa Pharmaceuticals PLC ADR

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibi...

    Ticker
    CNTA.US
    ISIN
    US1523091007
    CIK
    1847903
    Sector
    Healthcare
    Industry
    Biotechnology
    Country
    USA
    Address
    1 Ashley Road, Altrincham, United Kingdom, WA14 2DT